Chlorobenzene

Chlorobenzene

SCHEMBL4075795

COC(=O)CBr.Clc1ccccc1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
GSK3B P49841 2/20 0.42
TSHR P16473 2/20 0.42
PTGS2 P35354 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PTPN1 P18031 1/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
KLK7 P49862 1/20 0.39
AKT1 P31749 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL27283212 0.84 PTPN1 (0.52) POLBGSK3BTSHRMEN1KMT2A
Benzene SCHEMBL10509655 0.83 TSHR (0.48) POLBGSK3BTSHRMEN1KMT2A
Chlorobenzene SCHEMBL27856994 0.83 POLB (0.43) POLBTSHRPTGS2SLC6A4SLC6A3
Chlorobenzene SCHEMBL7570717 0.82 KLK7 (0.47) POLBTSHRPTGS2SLC6A4SLC6A3
Chlorobenzene SCHEMBL27889729 0.82 POLB (0.46) POLBTSHRPTGS2SLC6A4SLC6A3
Chlorobenzene SCHEMBL27773693 0.81 POLB (0.44) POLBTSHRPTGS2SLC6A4SLC6A3
Dimethyl Succinate SCHEMBL28197313 0.81 ALDH1A1 (0.51) POLBTSHRMEN1KMT2ALMNA
Chlorobenzene SCHEMBL27927236 0.79 TSHR (0.50) POLBTSHRPTGS2SLC6A4SLC6A3
SCHEMBL6314095 0.79 CYP3A4 (0.44) POLBGSK3BTSHRKMT2APTPN1
Chlorobenzene SCHEMBL28362949 0.79 KMT2A (0.47) POLBTSHRMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2084164-A2 IMPROVED PROCESS FOR PREPARING CLOPIDOGREL Teva Pharmaceutical Industries Ltd. (IL) 2009-08-05 EP claimed
US-20080287679-A1 Process for preparing clopidogrel TEVA PHARMACEUTICALS USA, INC. 2008-11-20 US claimed
WO-2008130642-A2 IMPROVED PROCESS FOR PREPARING CLOPIDOGREL TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-10-30 WO claimed
EP-2084164-A2 IMPROVED PROCESS FOR PREPARING CLOPIDOGREL Teva Pharmaceutical Industries Ltd. (IL) 2009-08-05 EP disclosed
US-20080287679-A1 Process for preparing clopidogrel TEVA PHARMACEUTICALS USA, INC. 2008-11-20 US disclosed
WO-2008130642-A2 IMPROVED PROCESS FOR PREPARING CLOPIDOGREL TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287679-A1 Process for preparing clopidogrel P2RY6, P2RY12, P2RY11 POLB 2974/4885GSK3B 1742/4885TSHR 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.